FDA, Congress Look To Nationalize Breast Density Reporting Requirements, Now In 13 States
This article was originally published in The Gray Sheet
Executive Summary
FDA hopes to finish drafting a proposed rule by early next year requiring mammography screening professionals to notify women and their physicians of dense breast tissue that may warrant further imaging follow-up with MRI and ultrasound. Meanwhile, a bill was recently introduced in Congress on the same topic.
You may also be interested in...
Evidence Lacking To Assess Added Dense-Breast, 3-D Mammo Cancer Screens, Task Force Says
In a draft recommendation, the U.S. Preventive Services Task Force says evidence is "insufficient" to assess 3D tomosynthesis for breast cancer screening, as well as for additional dense-breast screening by any modality.
New Product Briefs
DexCom’s “professional” continuous glucose monitor, Cook launches Zilver PTX drug-eluting peripheral stent and more product news.
House Panel Asks For ‘Prompt Review’ Of Evidence On Dense Breast Reporting
The House Appropriations Committee May 29 approved a flat-level 2015 FDA spending bill. The committee’s report language for the bill urges the agency to expedite its review of evidence supporting the need for breast density reporting in individuals’ mammography reports, and to keep focus on artificial pancreas systems.